ABSTRACT
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0 +/- 3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2 +/- 5.9 and 6.8 +/- 4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7 +/- 0.6 months and 10.0 +/- 2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.
Subject(s)
Antiviral Agents/therapeutic use , Guanine/analogs & derivatives , Hepatitis B Surface Antigens/blood , Hepatitis B e Antigens/blood , Hepatitis B, Chronic/drug therapy , Adult , Aged , Female , Guanine/therapeutic use , Hepatitis B, Chronic/immunology , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Fifty-two patients with acute Herpes Zoster were divided into two groups and treated respectively as follows: 25 received i.v. acyclovir and 27 received s.c. thymopentin, an immunomodulating drug. Both drugs proved effective in promoting the recovery from herpetic lesions and in relieving the painful symptomatology within approximately the same period of time. Thymopentin apparently has an antiphlogistic effect and is believed to prevent post-herpetic neuropathy through its immunomodulating activity. Further studies based on a larger number of patients would be necessary to confirm the results achieved and for statistical evaluation.
Subject(s)
Acyclovir/therapeutic use , Herpes Zoster/drug therapy , Thymopentin/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Middle AgedABSTRACT
The use of Acyclovir and early diagnosis greatly affect prognosis of the disease and a case that pathognomonically points to this need is reported.
Subject(s)
Acyclovir/therapeutic use , Encephalitis/etiology , Herpes Simplex/drug therapy , Acyclovir/administration & dosage , Electroencephalography , Encephalitis/diagnosis , Encephalitis/drug therapy , Female , Herpes Simplex/diagnosis , Humans , Middle Aged , Prognosis , Time Factors , Tomography, X-Ray ComputedABSTRACT
Forty-four patients admitted 1978-1986 were examined which suffered from leptospirosis. The authors bring a new contribution on the clinic of leptospirosis. They confirm that leptospirosis often assumes a polymorphic clinical degree. They stress the importance of an early diagnosis.
